A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma

British Journal of Haematology

Volumn 168, Issue 6, 2015, Pages 811-819

  Foss, Francine ^a   Advani, Ranjana ^b   Duvic, Madeleine ^c   Hymes, Kenneth B ^d   Intragumtornchai, Tanin ^e   Lekhakula, Arnuparp ^f   Shpilberg, Ofer ^g   Lerner, Adam ^h   Belt, Robert J ⁱ   Jacobsen, Eric D ^j   Laurent, Guy ^k   Ben Yehuda, Dina ^l   Beylot Barry, Marie ^m   Hillen, Uwe ⁿ   Knoblauch, Poul ^o   Bhat, Gajanan ^p   Chawla, Shanta ^p   Allen, Lee F ^p   Pohlman, Brad ^q  

^a YALE CANCER CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NEW YORK UNIVERSITY   (United States)

^e KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^f Department of Medicine Songlanagarind Hospital   (Thailand)

^g TEL AVIV UNIVERSITY   (Israel)

^h BOSTON MEDICAL CENTER   (United States)

ⁱ Kansas City Cancer Center   (United States)

^j DANA FARBER CANCER INSTITUTE   (United States)

^k CHU PURPAN   (France)

^l HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^m UNIVERSITÉ DE BORDEAUX   (France)

ⁿ UNIVERSITY HOSPITAL ESSEN   (Germany)

^o Topotarget   (Germany)

^p Spectrum Pharmaceuticals   (United States)

^q TAUSSIG CANCER INSTITUTE   (United States)

more..

Author keywords

Belinostat; Histone deacetylase inhibitors; Mycosis fungoides; Peripheral T cell Lymphoma; T cell lymphoma

Indexed keywords

BELINOSTAT; BEXAROTENE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; ETOPOSIDE; ETRETIN; GEMCITABINE; INTERFERON; ISOTRETINOIN; METHOTREXATE; PREDNISONE; PSORALEN; VINCRISTINE; VORINOSTAT; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SULFONAMIDE;

ADULT; AGED; ANOREXIA; APRAXIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CELLULITIS; CONSTIPATION; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; HEADACHE; HEART LEFT BUNDLE BRANCH BLOCK; HEART VENTRICLE FIBRILLATION; HISTOPATHOLOGY; HUMAN; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INJECTION SITE PAIN; INTERNATIONAL PROGNOSTIC INDEX; JUGULAR VEIN; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PARALYTIC ILEUS; PATIENT HISTORY OF THERAPY; PERIPHERAL EDEMA; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHOTOCHEMOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; SYSTEMIC THERAPY; THROMBOCYTOPENIA; VEIN THROMBOSIS; VOMITING; CLINICAL TRIAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOMA, T-CELL, PERIPHERAL; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INFUSIONS, INTRAVENOUS; LYMPHOMA, T-CELL, CUTANEOUS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84924081603     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13222     Document Type: Article

References (30)

1. Armitage, J.O. & Weisenburger, D.D. (1998) New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. Journal of Clinical Oncology, 16, 2780-2795.
2. Bots, M. & Johnstone, R.W. (2009) Rational combinations using HDAC inhibitors. Clinical Cancer Research, 15, 3970-3977.
3. Campo, E., Swerdlow, S.H., Harris, N.L., Pileri, S., Stein, H. & Jaffe, E.S. (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 117, 5019-5032.
4. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-López, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
5. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V., International Harmonization Project on Lymphoma. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
6. Coiffier, B., Pro, B., Prince, H.M., Foss, F., Sokol, L., Greenwood, M., Caballero, D., Borchmann, P., Morschhauser, F., Wilhelm, M., Pinter-Brown, L., Padmanabhan, S., Shustov, A., Nichols, J., Carroll, S., Balser, J., Balser, B. & Horwitz, S. (2012) Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. Journal of Clinical Oncology, 30, 631-636.
7. Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A.G., Myskowski, P., Crowley, C. & Yocum, R.C., Bexarotene Worldwide Study Group. (2001a) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Journal of Clinical Oncology, 19, 2456-2471.
8. Duvic, M., Martin, A.G., Kim, Y., Olsen, E., Wood, G.S., Crowley, C.A. & Yocum, R.C., Worldwide Bexarotene Study Group. (2001b) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Archives of Dermatology, 137, 581-593.
9. Gimsing, P., Hansen, M., Knudsen, L.M., Knoblauch, P., Christensen, I.J., Ooi, C.E. & Buhl-Jensen, P. (2008) A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia. European Journal of Haematology, 81, 170-176.
10. Jaffe, E.S. (2009) The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology: American Society of Hematology Education Program, 2009, 523-531.
11. Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S.C., Carey, N., Finn, P.W., Collins, L.S., Tumber, A., Ritchie, J.W., Jensen, P.B., Lichenstein, H.S. & Sehested, M. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. The Biochemical Journal, 409, 581-589.
12. Lassen, U., Molife, L.R., Sorensen, M., Engelholm, S.A., Vidal, L., Sinha, R., Penson, R.T., Buhl-Jensen, P., Crowley, E., Tjornelund, J., Knoblauch, P. & de Bono, J.S. (2010) A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours. British Journal of Cancer, 103, 12-17.
13. Lopez-Guillermo, A., Cid, J., Salar, A., López, A., Montalbán, C., Castrillo, J.M., González, M., Ribera, J.M., Brunet, S., García-Conde, J., Fernández de Sevilla, A., Bosch, F. & Montserrat, E. (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Annals of Oncology, 9, 849-855.
14. Ma, X., Ezzeldin, H.H. & Diasio, R.B. (2009) Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs, 69, 1911-1934.
15. Mann, B.S., Johnson, J.R., He, K., Sridhara, R., Abraham, S., Booth, B.P., Verbois, L., Morse, D.E., Jee, J.M., Pope, S., Harapanhalli, R.S., Dagher, R., Farrell, A., Justice, R. & Pazdur, R. (2007) Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous Tcell lymphoma. Clinical Cancer Research, 13, 2318-2322.
16. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guildelines®). Non-Hodgkin's Lymphoma. Version 2.2014. 27 March 2014. Available at www.nccn.org.
17. O'Connor, O.A., Pro, B., Pinter-Brown, L., Bartlett, N., Popplewell, L., Coiffier, B., Lechowicz, M.J., Savage, K.J., Shustov, A.R., Gisselbrecht, C., Jacobsen, E., Zinzani, P.L., Furman, R., Goy, A., Haioun, C., Crump, M., Zain, J.M., Hsi, E., Boyd, A. & Horwitz, S. (2011) Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. Journal of Clinical Oncology, 29, 1182-1189.
18. O'Leary, H.M. & Savage, K.J. (2008) Novel therapies in peripheral T-cell lymphomas. Current Oncology Reports, 10, 404-411.
19. Olsen, E.A., Kim, Y.H., Kuzel, T.M., Pacheco, T.R., Foss, F.M., Parker, S., Frankel, S.R., Chen, C., Ricker, J.L., Arduino, J.M. & Duvic, M. (2007) Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 25, 3109-3115.
20. Owonikoko, T.K., Ramalingam, S.S., Kanterewicz, B., Balius, T.E., Belani, C.P. & Hershberger, P.A. (2010) Vorinostat increases carboplatin and paclitaxel activity in non-small-cell lung cancer cells. International Journal of Cancer, 126, 743-755.
21. Plumb, J.A., Finn, P.W., Williams, R.J., Bandara, M.J., Romero, M.R., Watkins, C.J., La Thangue, N.B. & Brown, R. (2003) Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Molecular Cancer Therapeutics, 2, 721-728.
22. Prince, H.M., Duvic, M., Martin, A., Sterry, W., Assaf, C., Sun, Y., Straus, D., Acosta, M. & Negro-Vilar, A. (2010) Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. Journal of Clinical Oncology, 28, 1870-1877.
23. Pro, B., Advani, R., Brice, P., Bartlett, N.L., Rosenblatt, J.D., Illidge, T., Matous, J., Ramchandren, R., Fanale, M., Connors, J.M., Yang, Y., Sievers, E.L., Kennedy, D.A. & Shustov, A. (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. Journal of Clinical Oncology, 30, 2190-2196.
24. Qian, X., LaRochelle, W.J., Ara, G., Wu, F., Petersen, K.D., Thougaard, A., Sehested, M., Lichenstein, H.S. & Jeffers, M. (2006) Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Molecular Cancer Therapeutics, 5, 2086-2095.
25. Rudiger, T., Weisenburger, D.D., Anderson, J.R., Armitage, J.O., Diebold, J., MacLennan, K.A., Nathwani, B.N., Ullrich, F. & Müller-Hermelink, H.K.; Non-Hodgkin's Lymphoma Classification Project. (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Annals of Oncology, 13, 140-149.
26. Steele, N.L., Plumb, J.A., Vidal, L., Tjørnelund, J., Knoblauch, P., Rasmussen, A., Ooi, C.E., Buhl-Jensen, P., Brown, R., Evans, T.R. & DeBono, J.S. (2008) A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clinical Cancer Research, 14, 804-810.
27. Stevens, S.R., Ke, M.S., Parry, E.J., Mark, J. & Cooper, K.D. (2002) Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Archives of Dermatology, 138, 42-48.
28. Vose, J., Armitage, J. & Weisenburger, D. (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of Clinical Oncology, 26, 4124-4130.
29. Whittaker, S.J., Demierre, M.F., Kim, E.J., Rook, A.H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J.C., Samtsov, A., McCulloch, W. & Kim, Y.H. (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. Journal of Clinical Oncology, 28, 4485-4491.
30. Willemze, R., Jaffe, E.S., Burg, G., Cerroni, L., Berti, E., Swerdlow, S.H., Ralfkiaer, E., Chimenti, S., Diaz-Perez, J.L., Duncan, L.M., Grange, F., Harris, N.L., Kempf, W., Kerl, H., Kurrer, M., Knobler, R., Pimpinelli, N., Sander, C., Santucci, M., Sterry, W., Vermeer, M.H., Wechsler, J., Whittaker, S. & Meijer, C.J. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood, 105, 3768-3785.